1. Home
  2. IH vs TIL Comparison

IH vs TIL Comparison

Compare IH & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo iHuman Inc.

IH

iHuman Inc.

HOLD

Current Price

$1.75

Market Cap

82.8M

Sector

Real Estate

ML Signal

HOLD

Logo Instil Bio Inc.

TIL

Instil Bio Inc.

HOLD

Current Price

$8.61

Market Cap

74.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IH
TIL
Founded
1996
2018
Country
China
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
82.8M
74.7M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
IH
TIL
Price
$1.75
$8.61
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
$125.00
AVG Volume (30 Days)
10.5K
24.6K
Earning Date
03-31-2026
05-12-2026
Dividend Yield
5.65%
N/A
EPS Growth
N/A
6.06
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$7.30
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.55
$5.67
52 Week High
$3.60
$42.75

Technical Indicators

Market Signals
Indicator
IH
TIL
Relative Strength Index (RSI) 51.21 50.10
Support Level $1.74 $8.07
Resistance Level $2.29 $9.05
Average True Range (ATR) 0.11 0.48
MACD 0.01 0.05
Stochastic Oscillator 78.57 60.08

Price Performance

Historical Comparison
IH
TIL

About IH iHuman Inc.

iHuman Inc is a Chinese company that uses artificial intelligence to create technology-driven puzzle products for children, making parenting easier and children happier. The company offers a range of intellectual development products that are designed to make the child-rearing experience more manageable for parents while turning intellectual development into a fun journey for children. Its revenue is generated from subscription fees paid by users for premium content on their self-directed and interactive online applications, as well as offline products and other sources.

About TIL Instil Bio Inc.

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

Share on Social Networks: